Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct
May 10 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today introduced a milestone technology release,
setting the bar as the most comprehensive, end-to-end platform to
fully orchestrate study conduct for decentralized clinical trials
(DCTs) and increasingly agile designs that require both remote and
on-premise management.
The increase in demand for decentralized and agile
clinical research delivery models has required sponsors and CROs to
implement numerous point-solution technologies, often resulting in
disconnected processes that lead to study delays and threaten data
quality. Unlike many point solutions that enable components of
decentralization, the Science 37 technology platform delivers the
most comprehensive end-to-end solution in the industry.
Purpose-built to fully orchestrate study conduct
across all clinical trial stakeholders, Science 37’s platform
coordinates and unifies the stakeholder journey through every
clinical trial visit, with exceptional data-capture features to
increase compliance and generate the highest-quality data.
Science 37 has strengthened its SaaS platform with
advanced configuration features for visit plans and forms with its
newest release. The enhanced platform includes an eCOA library,
with assessments pre-approved by license holders, and enables
automation of the translation process to accelerate global study
rollout. Technology platform features are available as
full-service, self-service (SaaS), or self-service with support
from Science 37.
“There is a fundamental shift toward
decentralization, and the industry needs a proven integrated
solution,” said David Coman, Chief Executive Officer of Science 37.
“Our new platform release delivers this and more, with a front-end
that unifies all stakeholder journeys, improves compliance, and
generates high-fidelity data, coupled with a backend that delivers
speed, flexibility, and scale.”
Science 37's new platform release was developed in
collaboration with beta customers, including Boehringer Ingelheim
and Thermo Fisher Scientific.
“Boehringer Ingelheim believes in the value of
agile clinical trials to develop innovative drugs for patients
faster,” said Uli Broedl, Senior Vice President, Head of Global
Clinical Development and Operations at Boehringer Ingelheim. “We
are excited about our collaboration with Science 37 to develop this
highly innovative platform and look forward to leveraging its
capabilities in our efforts to advance patient-centric clinical
development.”
“Our long-standing partnership with Science 37 has
enabled Thermo Fisher Scientific to help establish the direction of
Science 37’s new technology release,” said David M. Johnston,
Ph.D., Senior Vice President and President, Clinical Research,
Thermo Fisher Scientific. “We look to leverage Science 37’s new
platform to build and deploy digital solutions ranging from eCOA
all the way through to full decentralized clinical trials.”
“With the proliferation of decentralization and the
increased use of digital technologies, sponsors face new challenges
with integration for various piecemeal solutions,” said Dr. Nimita
Limaye, Research VP, Life Sciences R&D Strategy and Technology,
IDC. “The industry needs a purpose-built technology platform that
can help streamline user experience across all settings of care,
ensure better compliance and drive quicker study builds. The latest
release of Science 37’s platform helps strengthens these
capabilities, and accelerate study timelines.”
To learn more about the Science 37 Technology
Platform, visit www.science37.com/technology.
About Science 37Science 37
Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal
access to clinical research—making it easier for patients and
providers to participate from anywhere and helping to accelerate
the development of treatments that impact patient lives. As a
pioneer of decentralized clinical trials, the Science 37 l
Operating System (OS) supports today’s more agile clinical research
designs with its full stack, end-to-end technology platform and
centralized networks of patient communities, telemedicine
investigators, mobile nurses, remote coordinators, provider
communities, and data and devices. Configurable to enable almost
any study type, the Science 37 OS enables up to 15x faster
enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES:
Drew BustosScience 37pr@science37.com
INVESTOR RELATIONS:
Caroline PaulGilmartin
GroupInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024